Effects of fluid restriction on measures of circulatory efficacy in adults with septic shock

Acta Anaesthesiologica Scandinavica

Volumn 61, Issue 4, 2017, Pages 390-398

  Hjortrup, P B ^a   Haase, N ^a   Wetterslev, J ^a   Lange, T ^b,c   Bundgaard, H ^d   Rasmussen, B S ^e   Dey, N ^f   Wilkman, E ^g   Christensen, L ^h   Lodahl, D ⁱ   Bestle, M ^j   Perner, A ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c PEKING UNIVERSITY   (China)

^d RANDERS REGIONAL HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f HERNING HOSPITAL   (Denmark)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h HOLBÆK HOSPITAL   (Denmark)

ⁱ HOLSTEBRO HOSPITAL   (Denmark)

^j HILLERØD HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; NORADRENALIN; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTICLE; CIRCULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FLUID RESTRICTION; FLUID RESUSCITATION; FLUID THERAPY; HEMODYNAMIC PARAMETERS; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SEPTIC SHOCK; TREATMENT OUTCOME; URINE VOLUME; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; INTENSIVE CARE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RESUSCITATION; SHOCK, SEPTIC; URODYNAMICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD CIRCULATION; CRITICAL CARE; FEMALE; FLUID THERAPY; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; NOREPINEPHRINE; RESUSCITATION; SHOCK, SEPTIC; URODYNAMICS; VASOCONSTRICTOR AGENTS;

EID: 85011706211     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12862     Document Type: Article

References (26)

1. Melo J, Peters JI. Low systemic vascular resistance: differential diagnosis and outcome. Crit Care 1999; 3: 71–7.
2. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483–90.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, MacHado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165–228.
4. Vincent J-L, Weil MH. Fluid challenge revisited. Crit Care Med 2006; 34: 1333–7.
5. Bihari S, Baldwin CE, Bersten AD, Ou J, Holt AW, Prakash S, Schnetz E, Fartasch M, van den Heuvel I, Vlasselaers D, Wouters PJ, Milants I, Ellger B, Vanhorebeek I, Van den Berghe G. Post resusicitation fluid boluses in severe sepsis or septic shock: prevalence and efficacy (price study). Crit Care Resusc 2013; 12: 66–70.
6. Cecconi M, Hofer C, Teboul J-L, Pettila V, Wilkman E, Molnar Z, Della Rocca G, Aldecoa C, Artigas A, Jog S, Sander M, Spies C, Lefrant J-Y, De Backer D. Fluid challenges in intensive care: the FENICE study: a global inception cohort study. Intensive Care Med 2015; 41: 1529–37.
7. Weisel RD, Vito L, Dennis RC, Valeri CR, Hechtman HB. Myocardial depression during sepsis. Am J Surg 1977; 133: 512–21.
8. Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilä V, Aaen A, Lodahl D, Berthelsen RE, Christensen H, Madsen MB, Winkel P, Wetterslev J, Perner A. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med 2016; 42: 1695–705.
9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–55.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–9.
11. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M, Sepsis Definitions Task F. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 775–87.
12. Glassford NJ, Mårtensson J, Eastwood GM, Jones SL, Tanaka A, Wilkman E, Bailey M, Bellomo R, Arabi Y, Bagshaw SM, Bannard-smith J, Bin D, Dubin A, Duranteau J, Echeverri J, Hoste E, Joannidis M, Kashani K, Kellum J, Kulkarni AP, Landoni G, Candal CL, Matejovic M, Yunos M, Anaes M, Nichol A, Straaten HOV, Perner A, Pettila V, Reinhart K, Richards G. Schneider AG. Defining the characteristics and expectations of fluid bolus therapy. A worldwide perspective. J Crit Care 2016; 35: 126–32.
13. Jansen TC, van Bommel J, Bakker J. Blood lactate monitoring in critically ill patients: a systematic health technology assessment. Crit Care Med 2009; 37: 2827–39.
14. Wacharasint P, Nakada T-a, Boyd JH, Russell JA, Walley KR. Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock (Augusta, Ga) 2012; 38: 4–10.
15. Glassford NJ, Eastwood GM, Bellomo R. Physiological changes after fluid bolus therapy in sepsis: a systematic review of contemporary data. Crit Care 2014; 18: 696.
16. van Haren FM, Sleigh J, Boerma EC, La Pine M, Bahr M, Pickkers P, van der Hoeven JG. Hypertonic fluid administration in patients with septic shock: a prospective randomized controlled pilot study. Shock 2012; 37: 268–75.
17. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013; 346: f839.
18. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest 2002; 121: 2000–8.
19. Nunes TS, Ladeira RT, Bafi AT, de Azevedo LC, Machado FR, Freitas FG. Duration of hemodynamic effects of crystalloids in patients with circulatory shock after initial resuscitation. Ann Intensive Care 2014; 4: 25.
20. Maitland K, George EC, Evans J, Kiguli S, Olupot-Olupot P, Akech SO, Opoka RO, Engoru C, Nyeko R, Mtove G, Reyburn H, Brent B, Nteziyaremye J, Mpoya A, Prevatt N, Dambisya CM, Semakula D, Ddungu A, Okuuny V, Wokulira R, Timbwa M, Otii B, Levin M, Crawley J, Babiker AG, Gibb DM. Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial. BMC Med 2013; 11: 68.
21. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM. Mortality after fluid bolus in African Children with severe infection. N Engl J Med 2011; 364: 2483–95.
22. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, DeBoisblanc B, Connors AF, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564–75.
23. Boyd JH, Forbes J, Nakada T-A, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39: 259–65.
24. Acheampong A, Vincent J-L. A positive fluid balance is an independent prognostic factor in patients with sepsis. Crit Care 2015; 19: 251.
25. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le GJ-R, Payen D, Investigators SOIAIP. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344–53.
26. Vaara ST, Korhonen A-M, Kaukonen K-M, Nisula S, Inkinen O, Hoppu S, Laurila JJ, Mildh L, Reinikainen M, Lund V, Parviainen I, Pettilä V. Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. Crit Care 2012; 16: R197.